CN Patent

CN110049764A — 用于治疗肾脏疾病或病症的联苯磺酰胺化合物

Assigned to Travere Therapeutics Inc · Expires 2019-07-23 · 7y expired

What this patent protects

提供了治疗方法，其包括施用具有结构(I)的化合物，或其药学上可接受的盐，或施用包含结构(I)的化合物或其药学上可接受的盐的药物组合物。

USPTO Abstract

提供了治疗方法，其包括施用具有结构(I)的化合物，或其药学上可接受的盐，或施用包含结构(I)的化合物或其药学上可接受的盐的药物组合物。

Drugs covered by this patent

atrasentan-hydrochloride (ATRASENTAN HYDROCHLORIDE)

Patent Metadata

Patent number: CN110049764A
Jurisdiction: CN
Classification: —
Expires: 2019-07-23
Drug substance claim: No
Drug product claim: No
Assignee: Travere Therapeutics Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.